Our professionals
Dr. Irene Ganan-Gomez
Principal investigator of the Myelodysplastic Neoplasia group.
Preferred dedication: Translational research on the pathogenic mechanisms driving the onset and progression of myelodysplastic syndromes
Be part of:
Cima Universidad de Navarra
Cancer Center Clínica Universidad de Navarra
INDEX H
15
Professional career
- Pharmacy Degree, Universidad de Alcalá (Madrid, Spain), 2008
- Master’s Degree in Cell Signaling and Therapeutic Targets, Universidad de Alcalá (Madrid, Spain), 2009
- PhD, Universidad de Alcalá (Madrid, Spain), 2013
- Postdoctoral Fellowship, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 2014-2019
- Instructor (Research Faculty Appointment), Department of Leukemia, The University of Texas MD Anderson Cancer Center, 2019-2023
- Investigator (Myelodysplastic Neoplasia group), Cancer Center Clínica Universidad de Navarra (Pamplona, Spain), 2023-present
RESEARCH AREAS
- Introduction to Research Activity Award (UAH, 2009)
- Research Staff Training Award (Council of Science and Technology, Castilla-La Mancha, Spain, 2009-2013)
- Jose Castillejo Travel Awards (Council of Science and Technology, Castilla-La Mancha, Spain, 2010, 2011)
- Kimberly Patterson Fellowship in Leukemia Research Award (MDACC Endowed Fellowship Award Program, 2016)
- Career Enhancement Award (MDACC Leukemia SPORE Program, 2019-2020)
- Marie Sklodowska-Curie Actions Postdoctoral Fellowship 2022 (European Research Agency, September 2023-December 2023)
- AECC Investigator Award 2022 (Asociación Española Contra el Cáncer, declined owing to incompatibility)
- Ramón y Cajal Award 2022 (Agencia Española de Investigación, September 2024-August 2029)
- Senior Talent Andía Award 2023 (Gobierno de Navarra, December 2023-December 2028)
AREAS OF INTEREST
Dr. Gañán Gómez’s research is aimed at identifying novel therapeutic targets for MDS patients in all disease stages, with a particular interest in unravelling the cell evasion mechanisms that enable MDS development and progression and the hierarchy-specific vulnerabilities sustaining the survival and expansion of MDS HSCs.
- Mechanisms of immune evasion in low-risk MDS
- Hematopoietic hierarchy-dependent oncogenic dependencies of MDS stem cells
Activity
As an educator
Dr. Gañán Gómez is co-directing the Doctoral Thesis entitled “Dissecting the Role of the Immune Microenvironment in the Onset of Myelodysplastic Syndromes”.As a researcher
Overall, Dr. Gañán Gómez’ scientific production has been published in high-impact journals (6 first-authored papers in Q1), widely cited (over 1500 total citations; h-index=15) and of high translational impact in biomedicine. In addition, along her career she has participated in a number of transfer-of-knowledge and service activities, sharing her expertise in HSC biology techniques with the scientific community in invited seminars and publications, participating in the training of multiple students and serving as a thesis evaluator for the international certification of a PhD candidate (Belen Sánchez Gómez, UAH, 2022). She is also a scientific manuscript reviewer for several Q1 journals and a member of the Spanish Group of Myelodysplastic Syndromes (GESMD).More information
Latest scientific publications
- Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Scientific Publication Apr 1, 2024 | Magazine: Clinical Cancer Research
- Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Scientific Publication Mar 18, 2024 | Magazine: Nature Communications